Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ALLO

Allogene Therapeutics Inc

May 21 • 04:00PM ET

2.69

Dollar change +0.10
Percentage change 3.86	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF VB IWN VBK IBB LABU SCHA DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	33.98%	Shs Outstand	170.85M	Perf Week	-9.12%
Market Cap	459.59M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	3.03%	Shs Float	106.11M	Perf Month	-20.88%
Income	-290.08M	PEG	-	EPS next Q	-0.37	Inst Own	61.84%	Short Float	31.92%	Perf Quarter	-39.41%
Sales	0.13M	P/S	3535.28	EPS this Y	25.19%	Inst Trans	4.07%	Short Ratio	14.84	Perf Half Y	-8.81%
Book/sh	2.71	P/B	0.99	EPS next Y	-2.41%	ROA	-43.52%	Short Interest	33.87M	Perf Year	-55.76%
Cash/sh	2.25	P/C	1.19	EPS next 5Y	1.00%	ROE	-55.06%	52W Range	2.23 - 6.41	Perf YTD	-16.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.18%	ROI	-52.72%	52W High	-58.00%	Beta	0.86
Dividend TTM	-	Quick Ratio	12.80	Sales past 5Y	-27.79%	Gross Margin	-7505.91%	52W Low	20.63%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	12.80	EPS Y/Y TTM	26.64%	Oper. Margin	-219123.85%	RSI (14)	35.45	Volatility	13.06% 8.43%
Employees	-	Debt/Eq	0.21	Sales Y/Y TTM	-24.70%	Profit Margin	-223140.00%	Recom	1.65	Target Price	11.51
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	43.72%	Payout	-	Rel Volume	2.17	Prev Close	2.59
Sales Surprise	96.43%	EPS Surprise	7.23%	Sales Q/Q	-57.69%	Earnings	May 13 AMC	Avg Volume	2.28M	Price	2.69
SMA20	-7.60%	SMA50	-26.39%	SMA200	-24.21%	Trades		Volume	4,963,031	Change	3.86%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Stifel	Buy → Hold	$44 → $18
Oct-08-21	Downgrade	Goldman	Buy → Neutral	$71 → $20
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy	$53
May-20-21	Upgrade	Truist	Hold → Buy	$34 → $41
May-14-21	Initiated	B. Riley Securities	Buy	$52

Show Previous Ratings

Today 01:56PM	Hedge Fund and Insider Trading News: Ken Griffin, Sanjay Shah, David Tepper, Stanley Druckenmiller, Michael Burry, Cevian Capital, Elliott Management, Millennium Management, Eisler Capital, Allogene Therapeutics Inc (ALLO), Carvana Co. (CVNA) and More (Insider Monkey)
08:16AM	Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating (MT Newswires)
May-16-24 08:13AM	HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating (MT Newswires)
May-14-24 12:56PM	Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag (Zacks)
09:14AM	Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating (MT Newswires)
08:21AM	Loading…
08:21AM	B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating (MT Newswires)
03:06AM	Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.07%
05:36PM	Allogene Therapeutics Prices $110 Million Offering (MT Newswires)
05:10PM	Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock (GlobeNewswire)
04:17PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:14PM	Allogene Therapeutics Q1 Loss Narrows, Revenue Declines (MT Newswires)
04:01PM	Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:30AM	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update (GlobeNewswire)
10:32AM	Loading…
Apr-26-24 10:32AM	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development (MT Newswires)
08:30AM	Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma (GlobeNewswire)
Apr-24-24 10:01AM	Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -9.79%
Apr-11-24 02:45PM	3 Meme Stocks to Sell and Replace With Meme Coins (InvestorPlace)
Apr-09-24 08:30AM	Allogene Therapeutics Announces Q2 Investor Conference Participation (GlobeNewswire)
Apr-08-24 08:46AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Mar-16-24 04:35PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 09:32AM	Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
07:04AM	Q4 2023 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.89%
05:34PM	Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ... (GuruFocus.com)
05:15PM	Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-13-24 12:15PM	Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology (Zacks)
08:50AM	Loading…
Mar-12-24 08:50AM	Allogene taps Arbor in pursuit of off-the-shelf CAR-T therapies for autoimmune disease (BioPharma Dive)
08:30AM	Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease (GlobeNewswire)
Mar-05-24 09:55AM	Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update (GlobeNewswire)
Feb-28-24 08:30AM	Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-16-24 08:30AM	Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia (GlobeNewswire)
Jan-16-24 04:05PM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-24 08:34AM	How Allogene (ALLO) Stock Stands Out in a Strong Industry (Zacks)
Jan-05-24 12:52PM	Allogene (ALLO) Down 20% on Strategic Changes in Pipeline (Zacks) -14.01%
08:25AM	UPDATE 2-Allogene to cut 22% of its workforce (Reuters)
08:13AM	Allogene to cut 22% of its workforce (Reuters)
Jan-04-24 04:15PM	Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
04:05PM	Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (GlobeNewswire)
11:05AM	Allogene to shift strategy in bid to reposition CAR-T (BioPharma Dive)
Jan-03-24 04:05PM	Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.01%
Dec-09-23 12:00PM	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Dec-01-23 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conference (GlobeNewswire) +7.23%
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-10-23 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-03-23 12:15PM	Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript (Insider Monkey) +17.85%
12:00PM	Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak and Dagger Technologies at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
12:00PM	Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
10:15AM	Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
Nov-02-23 07:33PM	Allogene Therapeutics Inc (ALLO) Reports Q3 2023 Financial Results (GuruFocus.com)
04:12PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
09:00AM	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology (GlobeNewswire)
Oct-30-23 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +9.09%
Oct-26-23 08:30AM	Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-16-23 09:26AM	The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics (Zacks)
08:30AM	Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer (GlobeNewswire)
Sep-27-23 09:09AM	Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-25-23 08:45AM	JP Morgan maintains Overweight recommendation on Allogene Therapeutics amid bullish market sentiment (Investing.com)
Sep-05-23 08:30AM	Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-14-23 08:30AM	Allogene Therapeutics Appoints Earl Douglas as General Counsel (GlobeNewswire)
Aug-03-23 11:20AM	Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss (Zacks) +9.59%
Aug-02-23 05:25PM	Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Allogene Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:02PM	Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
10:41AM	Too Cheap to Ignore: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money (TipRanks)
Jul-26-23 08:30AM	Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jun-15-23 09:30AM	Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
Jun-14-23 08:00AM	Allogene Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire) -12.54%
Jun-09-23 06:25PM	Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano (GlobeNewswire)
08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-03-23 09:00AM	Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-02-23 11:31AM	Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound? (Zacks) +5.45%
May-31-23 12:02PM	Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal (Zacks)
10:46AM	J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH (Zacks)
May-29-23 07:48AM	AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal (Zacks)
May-26-23 10:51AM	Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails (Zacks)
09:55AM	Wall Street Analysts See a 210.24% Upside in Allogene Therapeutics (ALLO): Can the Stock Really Move This High? (Zacks)
08:23AM	PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study (Zacks)
May-25-23 03:16PM	Immutep (IMMP) Up on Initial Data From Lung Cancer Study (Zacks)
May-24-23 11:37AM	Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data (Zacks) -5.95%
08:30AM	Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
08:14AM	INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up (Zacks)
May-22-23 08:16AM	We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-19-23 11:16AM	PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study (Zacks)
10:24AM	AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease (Zacks)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace)
12:45PM	MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study (Zacks)
11:15AM	Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing (Zacks)
May-17-23 02:19PM	Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag (Zacks)
11:21AM	PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up (Zacks)
11:13AM	Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag (Zacks)
May-16-23 09:31AM	Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases (Zacks) -9.05%

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Belldegrun Arie	Director	May 16 '24	Buy	2.90	1,724,137	4,999,997	1,724,137	May 20 09:33 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Jan 30 '24	Buy	3.60	190	683	819,590	Mar 06 09:52 PM
MESSEMER DEBORAH M.	Director	Dec 18 '23	Sale	2.70	18,640	50,317	62,456	Dec 20 04:26 PM
Mayo Stephen	Director	Aug 07 '23	Sale	4.29	10,000	42,855	25,328	Aug 09 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALLO

Allogene Therapeutics Inc

Upgrade your FINVIZ experience